Roche flunks its first-line degrader test
Persevera is a bust, but Roche hasn’t given up on the front line.
Betta joins Revolution in pan-RAS inhibition
BPI-572270 enters clinical trials.
Servier makes a rare big buy
The company pays $2.5bn for Day One and its approved drug Ojemda.
J&J receives Tecvayli/Darzalex nod
But it will be up to doctors whether to use the combo in Darzalex-exposed patients.
Like Sanofi, German Merck keeps the CEACAM5 faith
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
